KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 90 filers reported holding KARYOPHARM THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is 1.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $12,938,000 | +15.9% | 1,376,355 | +20.0% | 0.00% | 0.0% |
| Q3 2016 | $11,163,000 | +55.5% | 1,147,261 | +7.2% | 0.00% | 0.0% |
| Q2 2016 | $7,178,000 | -23.9% | 1,069,779 | +1.1% | 0.00% | 0.0% |
| Q1 2016 | $9,436,000 | -31.5% | 1,057,872 | +1.8% | 0.00% | -33.3% |
| Q4 2015 | $13,774,000 | +17.3% | 1,039,544 | -6.8% | 0.00% | 0.0% |
| Q3 2015 | $11,745,000 | -59.5% | 1,115,412 | +4.8% | 0.00% | -57.1% |
| Q2 2015 | $28,969,000 | +8.8% | 1,064,628 | +22.4% | 0.01% | +16.7% |
| Q1 2015 | $26,617,000 | -7.1% | 869,544 | +13.6% | 0.01% | -14.3% |
| Q4 2014 | $28,648,000 | +154.3% | 765,388 | +137.4% | 0.01% | +133.3% |
| Q3 2014 | $11,265,000 | -20.9% | 322,396 | +5.3% | 0.00% | -25.0% |
| Q2 2014 | $14,249,000 | +108.7% | 306,097 | +38.5% | 0.00% | +100.0% |
| Q1 2014 | $6,828,000 | +39.7% | 221,048 | +3.7% | 0.00% | +100.0% |
| Q4 2013 | $4,887,000 | – | 213,214 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,200,396 | $30,084,000 | 1.72% |
| TFS CAPITAL LLC | 105,040 | $987,000 | 0.26% |
| Tekla Capital Management LLC | 500,324 | $4,703,000 | 0.20% |
| Piermont Capital Management Inc. | 51,080 | $480,000 | 0.11% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 55,793 | $524,000 | 0.09% |
| Candriam S.C.A. | 390,000 | $3,666,000 | 0.08% |
| Virtus ETF Advisers LLC | 27,446 | $258,000 | 0.08% |
| SECOR Capital Advisors, LP | 66,484 | $625,000 | 0.08% |
| Trexquant Investment LP | 29,007 | $273,000 | 0.04% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 32,196 | $303,000 | 0.04% |